Eiger BioPharmaceuticals, Inc.·4

Mar 28, 9:13 PM ET

Eiger BioPharmaceuticals, Inc. 4

4 · Eiger BioPharmaceuticals, Inc. · Filed Mar 28, 2016

Insider Transaction Report

Form 4
Period: 2016-03-23
WELCH JAMES H
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2016-03-23+57,57157,571 total
    Exercise: $15.89Exp: 2026-03-23Common Stock (57,571 underlying)
Footnotes (2)
  • [F1]The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
  • [F2]The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION